SGX Google Yahoo TradingView

IX BIOPHARMA LTD. (42C) SGD 0.365   +6.85% +0.03

Portfolio Watchlist
AllFinancialBuy BackInsider Trading

IX Biopharma

2024-09-30
Financial Statements and Related Announcement::Auditor's Comments of Accounts

IX Biopharma

2024-08-12
General Announcement::Press Release - New Study Highlights CBD Wafer's Potential in Kidney Failure Patients

IX Biopharma

2024-07-24
Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Interest/ Changes in Interest of Director - Albert Ho Shing Tung

IX Biopharma

2024-07-22
REPL::Rights::Voluntary

IX Biopharma

2024-07-19
General Announcement::Issue and Listing of the Rights Shares and the Warrants

IX Biopharma

2024-07-15
General Announcement::Notice From Undertaking Shareholder Anson Properties Pte. Ltd.

IX Biopharma

2024-07-09
General Announcement::Press Release - Breakthrough Sublingual Wafers Raise NAD+ Levels, Enhance Well-Being in Human Trial

IX Biopharma

2024-07-02
Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Interest/ Changes in Interest of Director - Albert Ho Shing Tung

IX Biopharma

2024-07-02
Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Interest/ Changes in Interest of Director - Eddy Lee Yip Hang

IX Biopharma

2024-07-01
General Announcement::Proposed Renounceable Non-Underwritten Rights Cum Warrants Issue: Despatch of Notification and Forms

IX Biopharma

2024-06-26
REPL::Rights::Voluntary

IX Biopharma

2024-06-18
General Announcement::Notice of Adjustment to Conversion Price of 9% Convertible Bonds Principal Amount S$2 Million

IX Biopharma

2024-06-18
REPL::Rights::Voluntary

IX Biopharma

2024-06-11
REPL::Rights::Voluntary

IX Biopharma

2024-06-06
Rights::Voluntary

IX Biopharma

2024-03-20
General Announcement::Update For Shareholders

IX Biopharma

2024-03-11
General Announcement::Press Release - iX Biopharma Announces Development of Semaglutide Sublingual Wafer, iXB 401

IX Biopharma

2024-03-04
General Announcement::Press Release - iX Biopharma Unveils Novel NAD Wafers

IX Biopharma

2024-03-01
General Announcement::Termination Of Wafermine Licensing Agreement

IX Biopharma

2024-02-05
Financial Statements and Related Announcement::Half Yearly Results

IX Biopharma

2023-12-01
Employee Stock Option/ Share Scheme::Grant of Share Awards Pursuant to iX Performance Share Plan

IX Biopharma

2023-11-17
General Announcement::Notice Of Termination Of Wafermine Licensing Agreement

IX Biopharma

2023-11-14
General Announcement::Change of Address of Share Registrar and Place Where Register of Members and Index Is Kept

IX Biopharma

2023-11-10
General Announcement::Minutes of Annual General Meeting Held on 13 October 2023

IX Biopharma

2023-10-13
REPL::Annual General Meeting::Voluntary

IX Biopharma

2023-10-11
General Announcement::Responses to Questions from the Securities Investors Association (Singapore)

IX Biopharma

2023-10-06
General Announcement::Questions & Answers Provided by iX Biopharma Ltd for Annual General Meeting on 13 October 2023

IX Biopharma

2023-10-04
General Announcement::Corrigenda - Corporate Governance Reports 2022 and 2023

IX Biopharma

2023-09-29
General Announcement::Press Release - iX Biopharma Introduces MeltMed in USA

IX Biopharma

2023-09-25
Annual Reports and Related Documents::

IX Biopharma

2023-09-25
Annual General Meeting::Voluntary

IX Biopharma

2023-08-21
Financial Statements and Related Announcement::Full Yearly Results

IX Biopharma

2023-08-15
General Announcement::Press Release - iX Biopharma Develops Sublingual Interferon

IX Biopharma

2023-07-24
General Announcement::Proposed Issuance of Convertible Bonds of An Aggregate Principal Amount of S$2,000,000 - Completion

IX Biopharma

2023-07-17
General Announcement::Proposed Issuance of Convertible Bonds of S$2,000,000 - Receipt of Listing and Quotation Notice

IX Biopharma

2023-07-03
General Announcement::Proposed Issuance of Convertible Bonds of an Aggregate Principal Amount of S$2,000,000

IX Biopharma

2023-02-10
Financial Statements and Related Announcement::Half Yearly Results

IX Biopharma

2023-02-09
General Announcement::Press Release: iX Biopharma Successfully Completes Phase 1 Sublingual Dexmedetomidine Clinical Study

IX Biopharma

2022-12-02
General Announcement::Reconstitution of the Board Committees

IX Biopharma

2022-11-11
General Announcement::Minutes of Annual General Meeting Held on 14 October 2022

IX Biopharma

2022-11-07
General Announcement::Appointment of Independent Non-Executive Director and Re-Constitution of the Board

IX Biopharma

2022-11-07
Change - Announcement of Appointment::Appointment of Independent Non-Executive Director

IX Biopharma

2022-11-04
Employee Stock Option/ Share Scheme::Grant of Share Awards Pursuant to iX Performance Share Plan

IX Biopharma

2022-10-21
General Announcement::IX BIOPHARMA WINS BEST CBD SUBLINGUAL EDIBLE AWARD

IX Biopharma

2022-10-14
REPL::Annual General Meeting::Voluntary

IX Biopharma

2022-10-07
REPL::Annual General Meeting::Voluntary

IX Biopharma

2022-09-22
Change - Announcement of Cessation::Retirement of Independent and Non-Executive Director - Mr Low Weng Keong

IX Biopharma

2022-09-22
Annual Reports and Related Documents::

IX Biopharma

2022-09-22
Annual General Meeting::Voluntary

IX Biopharma

2022-08-28
General Announcement::Press Release - Launch of Sublingual Dexmedetomidine Programme

© 2026 Dividends.sg